Active, Not Recruiting
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers - CA209-817
Updated: 7 August, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologically confirmed Stage 4 or recurrent non-small cell lung cancer - Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer) - No prior systemic anticancer therapy (including EGFR and ALK inhibitors) - Tissue or Programmed death-ligand 1 (PD-L1) results available Cohort 1A Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) score 2 or - Eastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria as listed in the protocol Cohort C Inclusion Criteria: - High Tumor Mutation Burden Exclusion Criteria: - Untreated brain metastases - An active malignancy that requires concurrent intervention - Active, known or suspected autoimmune disease - Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
